Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
35 records found for “NCT07533019” · show all
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoMedical Dermatology Specialists, Phoenix, Arizona, 85006, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoDawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, 46250, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoTexas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue, San Antonio, Texas, 78235, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoUZ Gent, Ghent, 9000, Belgium
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoShanghai Skin Disease Hospital, Shanghai, 200071, China
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoNorthridge Clinical Trials, Northridge, California, 91325, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCura Clinical Research - Oxnard, Oxnard, California, 93030, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCura Clinical Research - Santa Clarita - Kelly Johnson Parkway, Santa Clarita, California, 91355, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoHealth Clinical Research, LLC, Miami, Florida, 33189, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoAdvanced Medical Research, PC., Sandy Springs, Georgia, 30328, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoBrigham and Women's Hospital, Boston, Massachusetts, 02115, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoRevival Research Institute, LLC, Troy, Michigan, 48084, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoEquity Medical, The Bronx, New York, 10455, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoAccurate Clinical Research, Inc, Humble, Texas, 77346, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoJordan Valley Dermatology & Research Center, South Jordan, Utah, 84095, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoAnima Diepenbeek, Diepenbeek, 3590, Belgium
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCentre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman, Liège, 4000, Belgium
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoINTERMED Groupe Sante, Chicoutimi, G7H 7Y8, Canada
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoDermEffects, London, N6H 5L5, Canada
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoDar Clinical Research - Ottawa - Hunt Club Road, Ottawa, K1V 1C1, Canada
1-317-615-4559
FAQOther Questions
- Shall I try low-fat diet for my vitiligo?
The link between dietary fat and autoimmune diseases like vitiligo is a compelling yet complex puzzle that continues to intrigue scientists. While the conversation is ongoing, o...
- What is the best therapy for localized vitiligo?
Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...
- Why Does the IRS Still Show an Old Revocation for VR Foundation?
IRS Status · A Short FAQ The old entry records the past. Publication 78 shows where VR Foundation stands today. Updated August 2026 · EIN 45-2498489 Tax records are rarely elega...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.